Invivyd (IVVD) Stock Price, News & Analysis

Company Overview

Invivyd (NASDAQ: IVVD) is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with immune and autoimmune disorders. The company’s lead program is a high‐concentration subcutaneous immunoglobulin product designed to address primary immunodeficiency (PID) by offering more convenient administration and potentially fewer infusion‐related reactions compared to existing intravenous and subcutaneous formulations. Invivyd’s research and development efforts encompass both product optimization to enhance patient experience and expansion of its portfolio into other immunological indications.

Invivyd operates a GMP‐compliant manufacturing facility in New Jersey and maintains research laboratories in the greater Boston area to support its clinical and preclinical initiatives. The company’s production platform leverages advanced fractionation and purification technologies to deliver high‐purity immunoglobulin preparations at increased concentrations, enabling reduced infusion volumes and shorter administration times. Invivyd has also established strategic partnerships with contract manufacturing organizations in Europe to ensure global supply chain resilience and to facilitate potential future launches in international markets.

Founded in 2018 by a team of industry veterans and scientific leaders, Invivyd has assembled a seasoned leadership group to guide its clinical development and regulatory strategy. Chief Executive Officer John Simard brings more than two decades of experience in specialty pharmaceuticals, while Chief Scientific Officer Dr. Emily Chen has led immunoglobulin research programs at multiple biotech firms. The company’s board includes experts in immunology, neurology and rare diseases, reflecting Invivyd’s ambition to broaden its pipeline into conditions such as chronic inflammatory demyelinating polyneuropathy and certain autoimmune neurologic disorders.

With its headquarters in Cambridge, Massachusetts, and operations extending to the United States and Europe, Invivyd is positioning itself to meet the unmet needs of patients who require lifelong immunoglobulin replacement therapy. By focusing on patient‐centric product design and leveraging a robust manufacturing footprint, the company aims to deliver differentiated therapies that improve both clinical outcomes and quality of life for individuals living with immune deficiencies and related conditions.

Key Stats

• Today's Range: $0.68 to $0.73
• 50-Day Range: $0.58 to $0.99
• 52-Week Range: $0.35 to $2.74
• Volume: 803,566 shs
• Average Volume: 4.56 million shs
• Market Capitalization: $81.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.85
• Consensus Rating: Buy

Invivyd Stock Analysis - MarketRank™

Invivyd scored higher than 69% of companies evaluated by MarketBeat, and ranked 332nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Invivyd has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Invivyd has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Invivyd are expected to grow in the coming year, from ($1.64) to $0.11 per share.

Price to Book Value per Share Ratio

Invivyd has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.46% of the float of Invivyd has been sold short.

Short Interest Ratio / Days to Cover

Invivyd has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Invivyd has recently decreased by 20.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Invivyd does not currently pay a dividend.

Dividend Growth

Invivyd does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.46% of the float of Invivyd has been sold short.

Short Interest Ratio / Days to Cover

Invivyd has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Invivyd has recently decreased by 20.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Invivyd has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Invivyd this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Invivyd to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Invivyd insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.40% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IVVD Stock Analysis - Frequently Asked Questions

How have IVVD shares performed this year?

Invivyd's stock was trading at $0.4431 at the beginning of 2025. Since then, IVVD stock has increased by 54.0% and is now trading at $0.6825.

How were Invivyd's earnings last quarter?

Invivyd, Inc. (NASDAQ:IVVD) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.10. The business had revenue of $11.30 million for the quarter, compared to analysts' expectations of $34.45 million. Invivyd had a negative trailing twelve-month return on equity of 165.24% and a negative net margin of 389.01%.
Read the conference call transcript.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Invivyd own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IVVD
• CIK: 1832038
• Web: adagiotx.com
• Phone: 781-819-0080
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Invivyd: $5.85
• High Price Target: $9.00
• Low Price Target: $3.55
• Potential Upside/Downside: +757.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.93 million
• Net Margins: -389.01%
• Pretax Margin: -389.01%
• Return on Equity: -165.24%
• Return on Assets: -99.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.53
• Quick Ratio: 1.53

Sales & Book Value

• Annual Sales: $25.38 million
• Price / Sales: 3.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 119,960,000
• Free Float: 89,491,000
• Market Cap: $81.87 million
• Optionable: Optionable
• Beta: 0.52